… observed in numerous primary central nervous system tumors as … -BRAF treated with an
analog of vemurafenib exhibit … cases of dramatic and sometimes-sustained response to BRAFi …

… the diagnoses of histiocytic sarcoma (HS), Langerhans cell sarcoma 192 and interdigitating
dendritic cell sarcoma, … We also thank Roche for providing vemurafenib and/or cobimetinib. …

… published cases of primary central nervous system histiocytic sarcoma (PCNSHS) … It has
been demonstrated that vemurafenib treatment resulted in a 3-month response in a BRAF p.…

… response to the BRAF-V600E inhibitor vemurafenib was reported in a refractory case of
BRAF-V600E-mutated primary CNS-… for histiocytic sarcoma of the central nervous system. Leuk …

… Histiocytic sarcoma (HS) is a malignant hematopoietic … On imaging, HS mimics a malignant
primary CNS tumor, with … V600E mutations may respond to inhibitors (eg, vemurafenib)…

… Histiocytic sarcoma (HS) is a highly malignant hematopoietic neoplasm that rarely arises in
the central nervous system (CNS)… Histiocytic sarcoma (HS) is a rare malignant hematopoietic …

… responses to a BRAF-V600E inhibitor, vemurafenib, have been shown in a refractory
BRAF-V600E-mutated primary CNS … of disseminated or CNS histiocytic sarcoma remains very …

… staining of BRAF V600E was negative in the … the BRAF inhibitor, vemurafenib, for histiocytic
sarcoma has been reported [11, 12]. A recent phase II study evaluating vemurafenib in BRAF …

… a dramatic impact on several cancers. One such target is … with MEK inhibitors in patients
with BRAF V600E-mutated tumors. FDA-… Patients received vemurafenib 960 mg twice per day …

… cells, but contained cell-free tumor DNA BRAF V600E-mutated (VAF = 47%) as measured by
… , the majority of patients develop resistance to vemurafenib + cobimetinib and dabrafenib + …